Finding genetic variants in patients with heart failure undergoing breast cancer treatment
Official title: Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Run by National Cancer Institute (NCI) · NCT02610426 · Data updated 2026-11-12
This study is trying to find genetic changes in patients who have heart failure while being treated for breast cancer to help improve future treatments and understand their risks better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | National Cancer Institute (NCI) NIH |
| Drugs / interventions | bevacizumab |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | March 25, 2014 |
| Main results expected | January 1, 2100 |
| Study ends | January 1, 2100 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT02610426 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include European American patients with available DNA who have developed congestive heart failure after breast cancer treatment, as well as African American patients with specific heart function criteria.
✕Probably not a fit
Patients who do not have a genetic predisposition to heart failure or who are not undergoing treatment for breast cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research focuses on using whole exome sequencing to identify genetic variants in germline DNA samples from patients who have congestive heart failure while receiving treatment for breast cancer. The study aims to analyze previously collected DNA samples to uncover rare variants that may influence the risk of developing heart failure in these patients. By understanding the genetic changes associated with heart failure, the research could lead to better biomarkers and treatment strategies for affected individuals.
Why it matters
Potential benefit: If successful, this study could help identify genetic markers that predict heart failure risk in breast cancer patients, leading to improved patient management.
How similar studies have gone: Other studies utilizing whole exome sequencing have shown promise in identifying genetic factors related to various conditions, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Where it's running
-
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mobile health navigation to improve breast cancer screening in Kenyan women
This study tests m-Health patient navigation tools to help women in Kenya access breast cancer screening and early detection services.
-
Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression
This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.
-
Environmental exposure checks in high-risk and early-onset breast cancer care
This study tests how patients and providers feel about using environmental exposure risk data in breast cancer care for women at average/high risk or with early-onset breast cancer.
-
CSF sample collection from people with metastatic breast cancer to see brain metastasis risk
This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.
-
Body composition and outcomes after breast reconstruction
This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.
-
Support tool for women with HR+ breast cancer on long-term endocrine therapy
This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.